Podcasts about helsinn

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUS865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Empowering Providers and Patients to Battle Advanced Biliary Tract Cancers: Expert Guidance on Integrating the Latest Evidence on Immunotherapy and Targeted Agents in Real-World Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through independent educational grants from AstraZeneca and Incyte Corporation.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMilind Javle, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Agios Pharmaceuticals Inc.; Array BioPharma Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; BeiGene; Biocartis; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; EMD Serono Inc.; GlaxoSmithKline; Halozyme Therapeutics; Helsinn; Incyte Corporation; Ipsen; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; OncoSil Medical Ltd; QED Therapeutics, Inc.; Servier Laboratories; Taiho Oncology, Inc.; and TransThera Biosciences Co. Ltd.Faculty/PlannerTanios Bekaii-Saab, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for (to self) AbbVie; Artiva Biotherapeutics; Aptitude Health; AstraZeneca; BeiGene; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Caladrius Biosciences; Celularity Inc.; Daiichi Sankyo Co., Ltd.; Deciphera Pharmaceuticals, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Foundation Medicine, Inc.; GlaxoSmithKline; Immuneering Corporation; Illumina, Inc.; Imugene Ltd.; Janssen Pharmaceuticals, Inc.; KANAPH Therapeutics Inc.; Natera, Inc.; Replimune Group Inc.; Sanofi; Sobi; Stemline Therapeutics, Inc.; Treos Bio Limited; Xilis, Inc; and Zai Lab. To institution: Arcus Biosciences, Inc.; Bayer Corporation; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merck KGaA; Merus; Pfizer; Seattle Genetics; and Servier Laboratories.Grant/Research Support from AbGenomics Corporation; Agios Pharmaceuticals, Inc.; Arcus Biosciences, Inc.; Arys; Atreca, Inc.; Bayer Corporation; Boston Biomedical Inc.; Bristol Myers Squibb; Celgene Corporation; Clovis Oncology; Eisai Co., Ltd.; Genentech, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; Lilly; Merus N.V.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Seattle Genetics. Research funding to Institution.Data Safety Monitoring Board for 1Globe Health Institute; AstraZeneca; Exelixis, Inc.; FibroGen, Inc.; Lilly; Merck & Co., Inc./Eisai Co., Ltd.; Pancreatic Cancer Action Network; Suzhou Kintor Pharmaceuticals, Inc.; and The Valley Hospital.Other Financial or Material Support from holding patents WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene. WO/2019/055687 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion.Faculty/PlannerRachna Shroff, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; QED Therapeutics; Servier Laboratories; Syros Pharmaceuticals, Inc.; and Zymeworks Inc.Grant/Research Support from Bayer; Bristol Myers Squibb; Exelixis, Inc.; IMV Inc.; Loxo Oncology, Inc.; Merck & Co., Inc.; Novocure, Inc.; NuCana; Pieris Pharmaceuticals, Inc.; QED Therapeutics; Rafael Pharmaceuticals, Inc.; Seagen; and Taiho Oncology, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

È uno degli argomenti in votazione il prossimo 13 giugno, verosimilmente il più sensibile: la legge sul Co2 che dovrebbe consentire alla Svizzera di velocizzare la transizione energetica ed abbattere le sue emissioni di gas serra del 50% entro il 2030 rispetto ai valori del 1990 fornendo un contributo in linea con quello degli altri paesi industrializzati nella lotta al riscaldamento climatico e ai suoi temuti effetti. Contro la legge è stato lanciato un referendum. Contestati sono soprattutto i suoi strumenti incentivanti: la nuova tassa sui biglietti aerei e gli aumenti del prezzo della benzina e della tassa sui combustibili previsti qualora la svolta verso le energie rinnovabili procedesse a un ritmo troppo lento. Oltre a riorientare le abitudini, questi strumenti consentirebbero però di raccogliere denaro da destinare al risanamento degli edifici, al sostegno dell'innovazione tecnologica, e che sarà anche in parte redistribuito alla popolazione. Ne discutiamo con due giovani politici:Diego Baratti, presidente dei giovani UDC e membro del comitato ticinese contro la legge sul Co2;Cristina Gardenghi, gran consigliera dei Verdi e coordinatrice del comitato dei giovani in Ticino a favore della legge.La puntata include:Un reportage sulle regioni periferiche, con testimonianze favorevoli e contrarie raccolte in alcune valli;Due interviste a due attori imprenditori, uno contrario alla nuova legge (Paolo Righetti, direttore di Righetti combustibili) e uno favorevole (Riccardo Braglia, CEO del gruppo Helsinn).undefined

AIPLA Podcast Network's Kemahl Franklyn is joined by Brad Pedersen and Brian Stanton to discuss the Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. case. Support the show (http://www.aipla.org)

“On sale” exception to patents.Also, i had no idea how to pronounce “palonosetron”, close ‘nuff i reckon.

On December 4, 2018, the Supreme Court heard argument in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc. This case arose out of a dispute over the validity of a patent covering a product used to reduce the likelihood of chemotherapy-induced nausea and vomiting. At issue in this case is whether agreements entered into by Helsinn more than one year prior to filing for patent protection put the invention “on sale” and thus would invalidate the patent. Although the meaning of “on sale” in the Patent Act was long believed to be settled, the 2011 America Invents Act (AIA) made changes to the statutory provisions that include the “on sale” bar. The question for the Supreme Court is whether these changes to the statute change the previous understanding of the term “on sale.”In April 2001, Helsinn entered into two agreements with MGI Pharma. Although these agreements were announced in a press release, specific information about the products, like dosing formulations, were omitted. In 2003, Helsinn filed a provisional patent application covering the product. Three patents arose from this provisional patent application prior to the enactment of the AIA; however, one patent was subject to the new provisions of the AIA.In 2011, Teva sought FDA approval to make a generic version of the patented product. Helsinn sued Teva for patent infringement based on this ANDA filing. Teva argued that the patent was invalid because Helsinn’s agreements with MGI put the product “on sale” before the relevant date. The district court rejected Teva’s argument, concluding that the AIA had changed the meaning of “on sale” to require the invention be made public by the sale. Because the dosing information was not provided in the press release regarding the agreements, the district court concluded the agreements did not make the invention public and there was no “on sale” bar. The Federal Circuit reversed, holding that inventions are made available to the public whenever there is a commercial offer for sale and that the sale is public even when the details of the invention are not disclosed to the public by the sale. Thus, the “on sale” bar applied to Helsinn’s patent. The U.S. Supreme Court then granted certiorari to address whether under the AIA, an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention.To the discuss the case, we have Kristen Osenga, Professor of Law at University of Richmond School of Law.

On December 4, 2018, the Supreme Court heard argument in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc. This case arose out of a dispute over the validity of a patent covering a product used to reduce the likelihood of chemotherapy-induced nausea and vomiting. At issue in this case is whether agreements entered into by Helsinn more than one year prior to filing for patent protection put the invention “on sale” and thus would invalidate the patent. Although the meaning of “on sale” in the Patent Act was long believed to be settled, the 2011 America Invents Act (AIA) made changes to the statutory provisions that include the “on sale” bar. The question for the Supreme Court is whether these changes to the statute change the previous understanding of the term “on sale.”In April 2001, Helsinn entered into two agreements with MGI Pharma. Although these agreements were announced in a press release, specific information about the products, like dosing formulations, were omitted. In 2003, Helsinn filed a provisional patent application covering the product. Three patents arose from this provisional patent application prior to the enactment of the AIA; however, one patent was subject to the new provisions of the AIA.In 2011, Teva sought FDA approval to make a generic version of the patented product. Helsinn sued Teva for patent infringement based on this ANDA filing. Teva argued that the patent was invalid because Helsinn’s agreements with MGI put the product “on sale” before the relevant date. The district court rejected Teva’s argument, concluding that the AIA had changed the meaning of “on sale” to require the invention be made public by the sale. Because the dosing information was not provided in the press release regarding the agreements, the district court concluded the agreements did not make the invention public and there was no “on sale” bar. The Federal Circuit reversed, holding that inventions are made available to the public whenever there is a commercial offer for sale and that the sale is public even when the details of the invention are not disclosed to the public by the sale. Thus, the “on sale” bar applied to Helsinn’s patent. The U.S. Supreme Court then granted certiorari to address whether under the AIA, an inventor’s sale of an invention to a third party that is obligated to keep the invention confidential qualifies as prior art for purposes of determining the patentability of the invention.To the discuss the case, we have Kristen Osenga, Professor of Law at University of Richmond School of Law.

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. | 12/04/18 | Docket #: 17-1229

Today in FirstWord:

Dr. Kevin Passero and his special guest Dr. Sreenivas Rao will be discussing nutritional support for cancer patients. DaxibeQOL, a product by Thorne Research, will be featured; it is a blend of branched-chain and other essential amino acids known to possibly promote anabolism, weight gain, lean muscle mass, and muscle strength. Dr. Sreenivas Rao has successfully managed programs for major pharmaceutical companies since 1994. He is currently president of OncoQOL, a joint business effort between two of the world's leading healthcare companies, Helsinn and Thorne Research, Inc. OncoQOL's mission is to provide pure, safe, evidence-based nutritional supplements and personal care products, together with information and education for medical professionals, patients, and caregivers.